Literature DB >> 15304592

Minocycline safety and tolerability in Huntington disease.

.   

Abstract

Minocycline is an antibiotic with anti-inflammatory and antiapoptotic properties that prolongs survival in a transgenic Huntington disease (HD) mouse model. In a double-blind, randomized, placebo-controlled study of minocycline in 60 HD patients, the authors determined that over 8 weeks, minocycline at 100 and 200 mg/day was well tolerated and safe in HD patients. Tolerability and adverse event frequency were similar between treatment and placebo groups.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304592     DOI: 10.1212/01.wnl.0000133403.30559.ff

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Lack of minocycline efficiency in genetic models of Huntington's disease.

Authors:  Stéphane Mievis; Marc Levivier; David Communi; Gilbert Vassart; Jacques Brotchi; Catherine Ledent; David Blum
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 2.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

3.  Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.

Authors:  Melissa J Armstrong; Janis M Miyasaki
Journal:  Neurology       Date:  2012-07-18       Impact factor: 9.910

Review 4.  The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.

Authors:  Jia Yi Li; Natalija Popovic; Patrik Brundin
Journal:  NeuroRx       Date:  2005-07

Review 5.  Prospects for minocycline neuroprotection.

Authors:  Jennifer M Plane; Yan Shen; David E Pleasure; Wenbin Deng
Journal:  Arch Neurol       Date:  2010-08-09

6.  Minocycline protects motor but not autonomic neurons after cauda equina injury.

Authors:  Thao X Hoang; Mahnaz Akhavan; Jun Wu; Leif A Havton
Journal:  Exp Brain Res       Date:  2008-05-14       Impact factor: 1.972

7.  A futility study of minocycline in Huntington's disease.

Authors: 
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

Review 8.  Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.

Authors:  Pawel M Switonski; Wojciech J Szlachcic; Agnieszka Gabka; Wlodzimierz J Krzyzosiak; Maciej Figiel
Journal:  Mol Neurobiol       Date:  2012-09-04       Impact factor: 5.590

Review 9.  Use of minocycline in viral infections.

Authors:  Kallol Dutta; Anirban Basu
Journal:  Indian J Med Res       Date:  2011-05       Impact factor: 2.375

10.  Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations.

Authors:  Tiago A Mestre; Monica Busse; Aileen M Davis; Lori Quinn; Filipe B Rodrigues; Jean-Marc Burgunder; Noelle E Carlozzi; Francis Walker; Aileen K Ho; Cristina Sampaio; Christopher G Goetz; Esther Cubo; Pablo Martinez-Martin; Glenn T Stebbins
Journal:  Mov Disord Clin Pract       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.